Opus Genetics (IRD) Other Operating Expenses (2010 - 2024)

Opus Genetics (IRD) reported Other Operating Expenses of $28.0 million for Q4 2024, up 234.29% quarter-over-quarter from $8.4 million in Q4 2020.

Opus Genetics (IRD) Other Operating Expenses (2010 - 2024) Analysis & Trends

Opus Genetics (IRD) has 7 years of Other Operating Expenses data on file, last reported at $28.0 million in Q4 2024.

Other Operating Expenses for Q4 2024 came in at $28.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $28.0 million (changed N/A YoY), and the FY2024 annual result was $28.0 million, changed N/A from the prior year.
Other Operating Expenses rose to $28.0 million in Q4 2024 per IRD's latest filing, from $8.4 million in the prior quarter.
Over five years, Other Operating Expenses peaked at $28.0 million in Q4 2024 and troughed at $2.1 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Opus Genetics	355.39 Mn	295.43 Mn	-

Download Data